Pfizer announced on April 2 to stop a late-stage study of the cancer drug Sutent (sunitinib) after the drug was not able to demonstrate a statistically significant improvement in survival rates of patients with a form of advanced breastcancer, when compared to capecitabine. Pfizer will however continue examining the drug in several other mid- and late-stage trials.